# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `full27_study-forensics-032_Claude_Haiku_1312f0`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T08:21:51.596268+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **73.1/100** (margin: 0.0)
**Failure modes:** missed_key_insight, named_not_explained, unsupported_intermediate_step
**Forensic flags:** 4
**Consistency findings:** 5
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.7/8 | 4.8/8 | 4.8/6 | 3.9/6 | 5.2/6 | 5.6/8 | 8.0/8 | 1.5/10 | 8.5/10 | **73.1/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `overclaim` [+] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** evidence_matches_claim, cautious_scope_control, none_or_minor, mechanism_not_demonstrated, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: fallacy |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "overclaim"


## Forensic Flags

### Claude Haiku

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "overclaim"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "overclaim"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "fallacy"


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 1.2/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[5]`: "Evaluated the accelerated approval claim: based on surrogate endpoints without outcome data, this represents a causal le"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[4]`: "LDL reduction is a validated surrogate marker for cardiovascular benefit, but surrogate benefit ≠ clinical benefit in al"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[0]`: "Whether the 65% LDL reduction is clinically meaningful in this specific population (familial hypercholesterolaemia on ma"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 5.2/6
  - (+) `alternative_hypotheses[1]`: "mechanism_vs_evidence: The mechanism (LDL lowering) is demonstrated, but the clinical consequence (cardiovascular protec"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 1/2 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[3]`: "Did I miss that this might be appropriate for accelerated approval? No — I noted that regulatory policy may permit this,"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.73, 563 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "a 12-week phase 2 trial with surrogate endpoints only identified the claims:"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "overclaim"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['fallacy'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "overclaim"
  - _Impacts: support_strength, structural_reasoning_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (1/18 content words)
  - `key_claims[0]`: "The core overclaim: executives claim 'cardiovascular protection' and 'transformed outcomes' based so"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/16 content words)
  - `key_claims[1]`: "Surrogate endpoint fallacy: LDL reduction is a validated risk factor, but reduction in a risk factor"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (1/17 content words)
  - `key_claims[2]`: "Temporal mismatch: accelerated approval is being pursued now, but outcome data won't exist for 4+ ye"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/14 content words)
  - `key_claims[3]`: "The trial is well-designed for its stated purpose (Phase 2 safety and biomarker assessment), but the"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "correlation_vs_causation: The claim that LDL reduction will 'transform outcomes' assumes causation f"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 11263ms

**Final Answer:** overclaim

**Confidence:** 0.92

**Assumptions:**
- The press report accurately represents what company executives stated
- The trial design is as described: 12-week duration, LDL and liver safety endpoints only
- No cardiovascular outcome data were collected during this Phase 2 trial
- The company is indeed pursuing accelerated approval based on surrogate endpoints
- LDL reduction is a validated surrogate marker for cardiovascular benefit, but surrogate benefit ≠ clinical benefit in all contexts

**Reasoning Steps:**
1. Identified the primary evidence: 65% LDL reduction in a 12-week Phase 2 trial with surrogate endpoints only
2. Identified the claims: executives called results a 'major breakthrough in cardiovascular protection' and said the drug would 'transform outcomes' for high-risk patients
3. Recognized the gap: surrogate endpoint (LDL) vs. claimed clinical benefit (cardiovascular protection, heart attack/stroke prevention)
4. Noted the temporal issue: no cardiovascular outcomes data exist; outcomes trial won't report for 4+ years
5. Assessed whether LDL reduction alone justifies claims about cardiovascular protection: while LDL is a validated risk factor, reduction in LDL does not guarantee reduction in cardiovascular events in all populations or drug classes
6. Evaluated the accelerated approval claim: based on surrogate endpoints without outcome data, this represents a causal leap from biomarker to clinical benefit

**Key Claims:**
- The core overclaim: executives claim 'cardiovascular protection' and 'transformed outcomes' based solely on a 12-week surrogate endpoint trial with no cardiovascular event data
- Surrogate endpoint fallacy: LDL reduction is a validated risk factor, but reduction in a risk factor does not guarantee clinical benefit (e.g., some drugs lower LDL but increase mortality)
- Temporal mismatch: accelerated approval is being pursued now, but outcome data won't exist for 4+ years, meaning the clinical benefit claim is entirely prospective
- The trial is well-designed for its stated purpose (Phase 2 safety and biomarker assessment), but the executive claims exceed what Phase 2 data can support

**Alternative Hypotheses:**
- correlation_vs_causation: The claim that LDL reduction will 'transform outcomes' assumes causation from a surrogate marker without outcome data
- mechanism_vs_evidence: The mechanism (LDL lowering) is demonstrated, but the clinical consequence (cardiovascular protection) is asserted without evidence

**Uncertainties:**
- Whether the 65% LDL reduction is clinically meaningful in this specific population (familial hypercholesterolaemia on maximum statin therapy) — this is a high-risk group where additional benefit may be real, but the claim still exceeds the evidence
- Whether the company's internal data or prior mechanistic evidence supports the leap from LDL to outcomes (not stated in the report)
- The exact language used by executives — the report paraphrases; if they said 'may help' vs. 'will transform,' the overclaim severity differs
- Regulatory context: whether accelerated approval pathways for lipid-lowering agents typically require outcome data (they often do not, but this is a policy question, not an epistemic one about the study)

**Self-Verification:**
- Did I conflate the trial design (solid for Phase 2) with the claims (overclaimed)? No — I distinguished between them.
- Did I assume LDL reduction is never sufficient for approval? No — I acknowledged it's a validated surrogate, but noted the gap between surrogate and clinical outcome.
- Did I fabricate missing data? No — I worked only with what was stated: no cardiovascular events tracked, outcomes trial pending.
- Did I miss that this might be appropriate for accelerated approval? No — I noted that regulatory policy may permit this, but the epistemic claim (cardiovascular protection) still exceeds the evidence.
- Is the overclaim clear and specific? Yes — the claim is that executives asserted clinical benefits (cardiovascular protection, transformed outcomes) based on a surrogate endpoint without outcome data.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.7/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 5.2/6 `########..`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **73.1/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.7/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (5.2/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 11.3s | 73.1/100 | 6.5 |

Failure modes observed: missed_key_insight, named_not_explained, unsupported_intermediate_step.
